Crohns & Colitis Foundation Perspectives

Host: Amy Lightner, MD When patients with inflammatory bowel disease find that certain treatments aren’t working for them, should we resort to surgical options? Tune in to hear Dr. Amy Lightner, Assistant Professor of Surgery and Immunology at the Cleveland Clinic, share her experience and key considerations. Published August 7, 2020

Host: Stacy Kahn, MD Inflammatory bowel disease in pediatric patients is not as uncommon as you may think. Dr. Stacy Kahn, Assistant Professor of Pediatrics at Boston Children’s Hospital, shares her experience with healthy diet plans, preparing families for transition, and more. Published August 7, 2020

Host: Ivy Ka Man Law, PhD A Specific Mutation in Muc2 Determines Early Dysbiosis in Colitis-Prone Winnie Mice Marina Liso, Stefania De Santis, Giulio Verna, Manuela Dicarlo, Maria Calasso, Angelo Santino, Isabella Gigante, Rajaraman Eri, Sathuwarman Raveenthiraraj, Anastasia Sobolewski, Valeria Palmitessa, Antonio Lippolis, Mauro Mastronardi, Raffaele Armentano, Grazia Serino, Maria De Angelis, Marcello Chieppa Background: Inflammatory bowel disease (IBD), including Crohn disease (CD) and ulcerative colitis (UC), is a multifactorial disorder characterized by chronic inflammation and altered gut barrier function. Dysbiosis, a condition defined by dysregulation of the gut microbiome, has been reported in patients with IBD and in experimental models of colitis. Although several factors have been implicated in directly affecting gut microbial composition, the genetic determinants impacting intestinal dysbiosis in IBD remain relatively unknown. Methods: We compared the microbiome of normal, uninflamed wild-ty

Host: Abdullah Abdussalam, MD Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Diana M Negoescu, Eva A Enns, PhD, Brooke Swanhorst, Bonnie Baumgartner, James P Campbell, Mark T Osterman, MD, Konstantinos Papamichael, PhD, Adam S Cheifetz, MD, Byron P Vaughn, MD Background: Therapeutic drug monitoring (TDM) is increasingly performed for Infliximab (IFX) in patients with Crohn's disease (CD). Reactive TDM is a cost-effective strategy to empiric IFX dose escalation. The cost-effectiveness of proactive TDM is unknown. The aim of this study is to assess the cost-effectiveness of proactive vs reactive TDM in a simulated population of CD patients on IFX. Methods: We developed a stochastic simulation model of CD patients on IFX and evaluated the expected health costs and outcomes of a proactive TDM strategy compared with a reactive strategy. The proactive strategy measured IFX concentration and antibody status every 6 months, or at the time of a flare, and dosed IFX to a therapeutic wi

Host: Matt Birnholz, MD Guest: Emeran Mayer, MD, PhD There’s no organ in the body that has such close connections with the brain as the gut, which can often result in pain for many of our patients with IBD. Listen in as Dr. Emeran Mayer joins Dr. Matt Birnholz to explain this mind-gut connection, why patients with IBD experience pain, and how providers can manage patients who experience pain when inflammation is and isn't present.

Host: Matt Birnholz, MD Guest: Uma Mahadevan, MD Whether you’re a seasoned veteran in the field or a newly practicing clinician, successful time management and work-life balance can be difficult to achieve. Tune in for key tips and tricks from Dr. Uma Mahadevan.

Host: Matt Birnholz, MD Guest: Kimberly Kearns, NP An advanced practice-provider’s role in treating patients with IBD is very critical, especially at a time when emerging data supports the multidisciplinary team’s positive impact on patients' experiences. Joining Dr. Matt Birnholz is nurse practitioner Kimberly Kearns to illuminate the impact advanced practice-providers have on patient outcomes.

Host: Matt Birnholz, MD Guest: Robbyn E. Sockolow, MD Creating a seamless road map for pediatric patients with irritable bowel disease (IBD) transitioning to an adult gastroenterologist can be as simple as having educational discussions with the patient and their families. Dr. Robbyn Sockolow joins Dr. Matt Birnholz to share key topics to emphasize with your patients and how you can assist in their transition to an adult practice.

Host: Matt Birnholz, MD Guest: Tiffany H. Taft, PsyD Since the brain-gut connection directly impacts the biopsychosocial well-being of IBD patients, Dr. Matt Birnholz sits down with Dr. Tiffany Taft, Director of Psychogastroenterology Research in the Division of Gastroenterology and Hepatology at Northwestern University, to discuss how integrating psychogastroenterology principles and techniques into your practice can help alleviate the burden of IBD on your patients.

Host: Matt Birnholz, MD Guest: Maria T. Abreu, MD As emerging data supports the idea that patients with IBD can be managed by focusing on the microbiome, discussing dietary needs, and using cognitive behavioral therapy, it’s important that providers are attentive to the changing paradigms. During the 2020 Crohn’s and Colitis Foundation Congress, Dr. Maria Abreu leverages her triple-threat perspective on bench research, clinical research, and clinical care to share how we can improve care for patients with IBD.

Host: Matt Birnholz, MD Guest: James D. Lewis, MD, MSCE The recipe for a healthy gut involves much more than just prescribing medications and diet restrictions. Treating the whole patient by identifying malnourishment, dermatologic conditions, and psychosocial needs can help ensure that IBD doesn’t have any negative impacts beyond the gut. Join Dr. Matt Birnholz as he digests the highlights from the 2020 Crohn's and Colitis Congress session "IBD: Beyond the Gut" with guest Dr. James Lewis.

Host: Matt Birnholz, MD Guest: Jeremy Adler, MD To catch us up to spend on the unique care needs of our pediatric patients with IBD, Dr. Matt Birnholz spoke with Dr. Jeremy Adler, Head of the Pediatric IBD Program at the University of Michigan, at the third annual Crohn’s & Colitis Congress in Austin, Texas.

Host: Matt Birnholz, MD Guest: Corey A. Siegel, MD, MS At the third annual Crohn’s & Colitis Congress in Austin, Texas, Co-Director of the IBD Program and Section Chief of Gastroenterology and Hepatology at the Dartmouth-Hitchcock Medical Center Dr. Corey Siegel sat down with Dr. Matt Birnholz to share his approach to presenting risk data to his IBD patients.

Host: Matt Birnholz, MD Guest: Frank Scott, MD Disease and drug monitoring can help us improve our approach to managing our patients’ IBD, but when’s the right time to perform that practice and how do we go about it? Joining Dr. Matt Birnholz at the third annual Crohn’s & Colitis Congress in Austin, Texas to answer those questions and more was Dr. Frank Scott, Assistant Professor of Medicine from the Crohn’s & Colitis Center at the University of Colorado.

Host: Jennifer Caudle, DO Guest: Neilanjan Nandi, MD Are you able to explain the difference between inflammatory bowel disease (IBD) and inflammatory bowel syndrome (IBS)? Test your knowledge with Dr. Jennifer Caudle and Dr. Neil Nandi, who tackles the common misconception that IBD and IBS are the same condition by providing essential tips for diagnosing and treating each of them.

Host: Jennifer Caudle, DO Guest: Neilanjan Nandi, MD Join Dr. Neilanjan Nandi as he discusses his experiences with patients presenting with GI issues, key symptoms to be on the lookout for, and how primary care clinicians and gastroenterologists can work together with their IBD patients to provide optimal care.

Host: Jenn Simmons, MD Guest: Jill K. Gaidos, MD The evolution of therapies for inflammatory bowel disease (IBD) has been nothing short of remarkable, which means it’s time that we take stock of the latest treatment targets, disease mechanism updates, drug pipeline developments, and patient safety considerations. And here to help us do just that is Dr. Jill Gaidos, Associate Professor of Medicine in the Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University.

Guest: Anish Patel, DO, FACG Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy Chao Chen, PhD, Abraham G Hartzema, PhD, Hong Xiao, PhD, Yu-Jung Wei, PhD, Naueen Chaudhry, MD, Ofor Ewelukwa, MD, Sarah C Glover, DO, Ellen M Zimmermann, MD BACKGROUND AND AIMS:Medication persistence, defined as the time from drug initiation to discontinuation of therapy, has been suggested as a proxy for real-world therapeutic benefit and safety. This study seeks to compare the persistence of biologic drugs among patients with inflammatory bowel disease (IBD). METHODS:Patients with newly diagnosed IBD were included in a retrospective study using Truven MarketScan database. Treatment persistence and switching was compared among biologic medications including infliximab, adalimumab, certolizumab, golimumab, and vedolizumab. Predictors for discontinuation and switching were evaluated using time-dependent propor

Guest: Robin Dalal, MD Improving the Quality of Inpatient Ulcerative Colitis Management: Promoting Evidence-Based Practice and Reducing Care Variation With an Inpatient Protocol Sara M Lewin, MD, Ryan A McConnell, MD, Roshan Patel, MD, Suzanne R Sharpton, MD, MAS, Fernando Velayos, MD, MPH, Uma Mahadevan, MD BACKGROUND:Hospitalization for ulcerative colitis is a high-risk period associated with increased risk of Clostridium difficile infection, thromboembolism, and opiate use. The study aim was to develop and implement a quality-improvement intervention for inpatient ulcerative colitis management that standardizes gastroenterology consultant recommendations and improves delivery of evidence-based care. METHODS:All adult patients hospitalized for ulcerative colitis between July 1, 2014, and December 31, 2017, who received intravenous corticosteroids were included. On July 1, 2016, the UCSF Inpatient Ulcerative Colitis Protocol was implemented, featuring standardized core recommendations and a daily checkl

Host: Jennifer Caudle, DO To gain more insights into how inflammatory bowel disease (IBD) affects our young patients, Dr. Jennifer Caudle connects with Caroline, a 12-year-old patient who was diagnosed with IBD at the age of 4, and her parents, Preston and Rachelle, about the challenges they face and the strategies and solutions available that can help children and teens like Caroline manage this condition.